Developmental differences in the expression and modulation of extracellular matrix proteases and inhibitors in mouse skin fibroblasts.
To investigate developmental differences in the wound repair process between fetal and adult skin fibroblasts, we studied the expression of plasminogen activator, plasminogen activator inhibitor, matrix metalloproteinase, and tissue inhibitor of metalloproteinase in E-15, E-17, newborn and adult mouse skin fibroblasts cultured within three dimensional matrices of either collagen or fibrin. Fibrin overlay and reverse overlay analyses revealed that mouse skin fibroblasts secreted tissue plasminogen activator and type1 plasminogen activator inhibitor. However, only E-15 and E-17 fibroblasts secreted the active form of tissue plasminogen activator, while in newborn and adult fibroblasts tissue plasminogen activator was conjugated to type1 plasminogen activator inhibitor. Only adult fibroblasts expressed a high level of active type1 plasminogen activator inhibitor. Gelatin zymography revealed that the predominant matrix metalloproteinase secreted by all the mouse fibroblasts was gelatinase A (matrix metalloproteinase -2). Matrix metalloproteinase -2 was partially activated in the adult fibroblasts cultured within a collagen matrix. The tissue inhibitor of metalloproteinase-2 was expressed by all fibroblasts, but levels were highest in the newborn and adult fibroblasts. When E-15 fibroblasts were cultured within a fibrin matrix, tissue plasminogen activator was downregulated. Transforming growth factor-betadownregulated tissue plasminogen activator while upregulating type1 plasminogen activator inhibitor, and platelet-derived growth factor enhanced tissue plasminogen activator expression in E-15 fibroblasts. Therefore, plasminogen activator and its inhibitor, and matrix metalloproteinase and its associated tissue inhibitor are differentially expressed in fetal and adult fibroblasts, and their expression is controlled by extracellular matrix components and growth factors present in wounds.
Island
E
E
Department of Surgery, Childrens Hospital Los Angeles, University of Southern California School of Medicine, Los Angeles, CA 90027, USA.
Wu
H
H
Warburton
D
D
Anderson
K
K
Tuan
T L
TL
D000818:Animals; D015153:Blotting, Western; D002478:Cells, Cultured; D003094:Collagen / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D005109:Extracellular Matrix / Q000378:metabolism; D005333:Fetus / Q000201:enzymology; D005337:Fibrin / Q000494:pharmacology; D005347:Fibroblasts / Q000201:enzymology*; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D051379:Mice; D010960:Plasminogen Activators / Q000378:metabolism*; D015849:Plasminogen Inactivators / Q000378:metabolism*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D012867:Skin / Q000166:cytology* / Q000201:enzymology; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism*; D016212:Transforming Growth Factor beta / Q000494:pharmacology
D015849:Plasminogen Inactivators; D010982:Platelet-Derived Growth Factor; D019714:Tissue Inhibitor of Metalloproteinases; D016212:Transforming Growth Factor beta; D005337:Fibrin; D003094:Collagen; D010960:Plasminogen Activators; D020782:Matrix Metalloproteinases